Skip to main content
Erschienen in: Journal of Cachexia, Sarcopenia and Muscle 2/2013

01.06.2013 | Editorial

Why cachexia kills: examining the causality of poor outcomes in wasting conditions

verfasst von: Kamyar Kalantar-Zadeh, Connie Rhee, John J. Sim, Peter Stenvinkel, Stefan D. Anker, Csaba P. Kovesdy

Erschienen in: Journal of Cachexia, Sarcopenia and Muscle | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Weight loss is the hallmark of any progressive acute or chronic disease state. In its extreme form of significant lean body mass (including skeletal muscle) and fat loss, it is referred to as cachexia. It has been known for millennia that muscle and fat wasting leads to poor outcomes including death. On one hand, conditions and risk factors that lead to cachexia and inadequate nutrition may independently lead to increased mortality. Additionaly, cachexia per se, withdrawal of nutritional support in progressive cachexia, and advanced age may lead to death via cachexia-specific pathways. Despite the strong and consistent association of cachexia with mortality, no unifying mechanism has yet been suggested as to why wasting conditions are associated with an exceptionally high mortality risk. Hence, the causality of the cachexia–death association, even though it is biologically plausible, is widely unknown. This century-long uncertainty may have played a role as to why the field of cachexia treatment development has not shown major advances over the past decades. We suggest that cachexia-associated relative thrombocytosis and platelet activation may play a causal role in cachexia-related death, while other mechanisms may also contribute including arrhythmia-associated sudden deaths, endocrine disorders such as hypothyroidism, and immune system compromise leading to infectious events and deaths. Multidimensional research including examining biologically plausible models is urgently needed to investigate the causality of the cachexia–death association.
Literatur
1.
Zurück zum Zitat Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793–9.PubMedCrossRef Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793–9.PubMedCrossRef
2.
Zurück zum Zitat Farkas J, von Haehling S, Kalantar-Zadeh K, Morley JE, Anker SD, Lainscak M. Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle. 2013. doi:10.1007/s13539-013-0105-y Farkas J, von Haehling S, Kalantar-Zadeh K, Morley JE, Anker SD, Lainscak M. Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle. 2013. doi:10.​1007/​s13539-013-0105-y
3.
Zurück zum Zitat Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295–300.PubMed Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295–300.PubMed
4.
Zurück zum Zitat Kovesdy CP, Kalantar-Zadeh K. Observational studies versus randomized controlled trials: avenues to causal inference in nephrology. Adv Chronic Kidney Dis. 2012;19:11–8.PubMedCrossRef Kovesdy CP, Kalantar-Zadeh K. Observational studies versus randomized controlled trials: avenues to causal inference in nephrology. Adv Chronic Kidney Dis. 2012;19:11–8.PubMedCrossRef
5.
Zurück zum Zitat Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health. 2005;95:S144–50.PubMedCrossRef Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health. 2005;95:S144–50.PubMedCrossRef
6.
Zurück zum Zitat Molnar MZ, Streja E, Kovesdy CP, Budoff MJ, Nissenson AR, Krishnan M, et al. High platelet count as a link between renal cachexia and cardiovascular mortality in end-stage renal disease patients. Am J Clin Nutr. 2011;94:945–54.PubMedCrossRef Molnar MZ, Streja E, Kovesdy CP, Budoff MJ, Nissenson AR, Krishnan M, et al. High platelet count as a link between renal cachexia and cardiovascular mortality in end-stage renal disease patients. Am J Clin Nutr. 2011;94:945–54.PubMedCrossRef
7.
Zurück zum Zitat Streja E, Kovesdy CP, Greenland S, Kopple JD, McAllister CJ, Nissenson AR, et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis. 2008;52:727–36.PubMedCrossRef Streja E, Kovesdy CP, Greenland S, Kopple JD, McAllister CJ, Nissenson AR, et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis. 2008;52:727–36.PubMedCrossRef
8.
Zurück zum Zitat Keung YK, Owen J. Iron deficiency and thrombosis: literature review. Clin Appl Thromb Hemost. 2004;10:387–91.PubMedCrossRef Keung YK, Owen J. Iron deficiency and thrombosis: literature review. Clin Appl Thromb Hemost. 2004;10:387–91.PubMedCrossRef
10.
Zurück zum Zitat Lee PS, Sampath K, Karumanchi SA, Tamez H, Bhan I, Isakova T, et al. Plasma gelsolin and circulating actin correlate with hemodialysis mortality. J Am Soc Nephrol. 2009;20:1140–8.PubMedCrossRef Lee PS, Sampath K, Karumanchi SA, Tamez H, Bhan I, Isakova T, et al. Plasma gelsolin and circulating actin correlate with hemodialysis mortality. J Am Soc Nephrol. 2009;20:1140–8.PubMedCrossRef
11.
Zurück zum Zitat Kovesdy CP, Kalantar-Zadeh K. Why is protein–energy wasting associated with mortality in chronic kidney disease? Semin Nephrol. 2009;29:3–14.PubMedCrossRef Kovesdy CP, Kalantar-Zadeh K. Why is protein–energy wasting associated with mortality in chronic kidney disease? Semin Nephrol. 2009;29:3–14.PubMedCrossRef
12.
Zurück zum Zitat Webb JG, Kiess MC, Chan-Yan CC. Malnutrition and the heart. CMAJ. 1986;135:753–8.PubMed Webb JG, Kiess MC, Chan-Yan CC. Malnutrition and the heart. CMAJ. 1986;135:753–8.PubMed
13.
Zurück zum Zitat Doehner W, Anker SD. Beta blockers and glucose metabolism in chronic heart failure: friend or foe? Clin Res Cardiol. 2008;97:21–3.PubMedCrossRef Doehner W, Anker SD. Beta blockers and glucose metabolism in chronic heart failure: friend or foe? Clin Res Cardiol. 2008;97:21–3.PubMedCrossRef
14.
Zurück zum Zitat Rauchhaus M, Koloczek V, Volk H, Kemp M, Niebauer J, Francis DP, et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol. 2000;76:125–33.PubMedCrossRef Rauchhaus M, Koloczek V, Volk H, Kemp M, Niebauer J, Francis DP, et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol. 2000;76:125–33.PubMedCrossRef
15.
Zurück zum Zitat Sandek A, Bjarnason I, Volk HD, Crane R, Meddings JB, Niebauer J, et al. Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. Int J Cardiol. 2012;157:80–5.PubMedCrossRef Sandek A, Bjarnason I, Volk HD, Crane R, Meddings JB, Niebauer J, et al. Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. Int J Cardiol. 2012;157:80–5.PubMedCrossRef
16.
Zurück zum Zitat Pedroso FE, Spalding PB, Cheung MC, Yang R, Gutierrez JC, Bonetto A, et al. Inflammation, organomegaly, and muscle wasting despite hyperphagia in a mouse model of burn cachexia. J Cachexia Sarcopenia Muscle. 2012;3:199–211.PubMedCrossRef Pedroso FE, Spalding PB, Cheung MC, Yang R, Gutierrez JC, Bonetto A, et al. Inflammation, organomegaly, and muscle wasting despite hyperphagia in a mouse model of burn cachexia. J Cachexia Sarcopenia Muscle. 2012;3:199–211.PubMedCrossRef
17.
Zurück zum Zitat Tschirner A, von Haehling S, Palus S, Doehner W, Anker SD, Springer J. Ursodeoxycholic acid treatment in a rat model of cancer cachexia. J Cachexia Sarcopenia Muscle. 2012;3:31–6.PubMedCrossRef Tschirner A, von Haehling S, Palus S, Doehner W, Anker SD, Springer J. Ursodeoxycholic acid treatment in a rat model of cancer cachexia. J Cachexia Sarcopenia Muscle. 2012;3:31–6.PubMedCrossRef
18.
Zurück zum Zitat Utech AE, Tadros EM, Hayes TG, Garcia JM. Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. J Cachexia Sarcopenia Muscle. 2012;3:245–51.PubMedCrossRef Utech AE, Tadros EM, Hayes TG, Garcia JM. Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. J Cachexia Sarcopenia Muscle. 2012;3:245–51.PubMedCrossRef
Metadaten
Titel
Why cachexia kills: examining the causality of poor outcomes in wasting conditions
verfasst von
Kamyar Kalantar-Zadeh
Connie Rhee
John J. Sim
Peter Stenvinkel
Stefan D. Anker
Csaba P. Kovesdy
Publikationsdatum
01.06.2013
Verlag
Springer-Verlag
Erschienen in
Journal of Cachexia, Sarcopenia and Muscle / Ausgabe 2/2013
Print ISSN: 2190-5991
Elektronische ISSN: 2190-6009
DOI
https://doi.org/10.1007/s13539-013-0111-0

Weitere Artikel der Ausgabe 2/2013

Journal of Cachexia, Sarcopenia and Muscle 2/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.